Furthermore, we demonstrate mechanistically that CYC065’s effects against high-risk MYCN-driven NB are a result of CDK9 inhibition resulting in selective loss of MYCN nascent transcription, which in turn leads to cell growth arrest and, in addition, sensitizes NB cells to apoptosis upon concomitant inhibition of CDK2 by the drug. The gene discussed is MYCN; the disease is neuroblastoma.